达沙替尼联合培门冬酶化疗方案治疗Ph阳性急性淋巴细胞白血病患者的效果

Effect of Combination of Dasatinib and Pegaspargase Chemotherapy in the Treatment of Ph Positive Acute Lymphoblastic Leukemia Patients

目的:探讨达沙替尼联合培门冬酶化疗方案治疗Ph阳性急性淋巴细胞白血病患者的效果。方法:按照简单随机化法将本院2018年6月-2019年6月100例Ph阳性急性淋巴细胞白血病患者分组,对照组(n=50)给培门冬酶化疗方案治疗,观察组(n=50)则在对照组的基础上给予达沙替尼治疗。两组均连续治疗2个疗程。对比两组临床疗效,治疗前后血清胸苷激酶1(thymidine kinase 1,TK1)、尿激酶型纤溶酶原激活物(urokinase-type plasminogen activator,uPA)水平变化。结果:观察组患者临床总有效率为90.00%,高于对照组的64.00%,差异有统计学意义(P<0.05);与治疗前相比,治疗后两组患者的血清TK1、uPA水平均降低,观察组低于对照组,差异均有统计学意义(P<0.05)。结论:达沙替尼联合培门冬酶化疗方案治疗可以提高Ph阳性急性淋巴细胞白血病患者的治疗效果,降低TK1、uPA水平。

Objective:To investigate the effect of combination of Dasatinib and Pegaspargase chemotherapy in the treatment of Ph positive acute lymphoblastic leukemia.Method:According to simple randomization method,100 patients with Ph positive acute lymphoblastic leukemia were divided into groups from June 2018 to June 2019.Fifty patients in the control group were treated with Pegaspargase chemotherapy,and 50 patients in the observation group were treated with Dasatinib on the basis of the control group.and two groups were treated for 2 courses.The clinical effect of the two groups was compared,and the serum thymidine kinase 1 (TK1) and urokinase-type plasminogen activator (uPA) levels were changed before and after treatment.Result:The total effective rate of the observation group was 90.00%,higher than that of the control group 64.00%,the difference was statistically significant (P<0.05).Compared with before treatment,the levels of serum TK1 and uPA in the two groups decreased after treatment,and the levels in the observation group were lower than those in the control group,the differences were statistically significant (P<0.05).Conclusion:The combination of Dasatinib and Pegaspargase chemotherapy can improve the therapeutic effect of Ph positive patients with acute lymphoblastic leukemia and reduce the level of serum TK1 and uPA.